Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types ...

The mutation burden in DLBCL varies significantly based on patient sex and age, according to recent findings published in ...

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

In terms of efficacy and safety, four out of the six non-GCB DLBCL subjects achieved an objective response, with one attaining stable disease. This resulted in a disease control rate of 83%.

Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

“These results represent a promising step forward in improving outcomes for DLBCL patients and underscores ... in tackling this challenging disease. We believe that the combination of SLS009 ...

Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD ...

Today, the Honourable Mark Holland, Canada's Minister of Health, and the Honourable John Main , Nunavut's Minister of Health, announced a bilateral agreement investing over $7.3 million over three ...